Stem cell therapy: a paradigm shift in reversing type 1 diabetes mellitus

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas, necessitating lifelong insulin therapy. Despite advancements in glucose monitoring and insulin delivery, current treatments remain palliative and fail to address the root autoimmune pathology or restore endogenous insulin production. Stem cell therapy has emerged as a promising curative approach due to its dual capacity to regenerate beta cells and modulate immune responses by suppressing autoreactive immune cells and promoting immune tolerance. This review explores the various types of stem cells under investigation - embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, and pancreatic progenitor cells - highlighting their unique advantages and limitations. We delve into mechanisms of action including cell differentiation protocols, immune protection strategies such as encapsulation, and the synergistic use of gene editing to enhance graft survival. Recent preclinical successes and early-phase clinical trials have demonstrated partial insulin independence in up to 40% of participants, with others showing 20-30% reductions in exogenous insulin requirements and measurable increases in C-peptide levels sustained for 6-12 months. However, challenges remain in achieving scalable production, long-term engraftment, and immune tolerance. As research continues to overcome these barriers, stem cell therapy holds transformative potential to shift T1DM treatment from management to functional cure.